Who are ACP-104's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Wakix, Floxin, Syncurine, Eramin, Betahistine Extended Release formulation, Merislon.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acp-104.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ACP-104 — Competitive Intelligence Brief

ACP-104 (ACP-104) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine H3 receptor inverse agonist. Area: Neurology.

phase 2 Histamine H3 receptor inverse agonist Histamine H3 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ACP-104 (ACP-104) — ACADIA Pharmaceuticals Inc.. ACP-104 is a selective histamine H3 receptor inverse agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACP-104 TARGET	ACP-104	ACADIA Pharmaceuticals Inc.	phase 2	Histamine H3 receptor inverse agonist	Histamine H3 receptor
Wakix	PITOLISANT	Harmony	marketed		Histamine H3 receptor	2019-01-01
Floxin	OFLOXACIN		marketed	Quinolone Antimicrobial [EPC]	Histamine H3 receptor	1990-01-01
Syncurine	DECAMETHONIUM		marketed	decamethonium	Acetylcholinesterase, Histamine H3 receptor, Muscarinic acetylcholine receptor M2	1975-01-01
Eramin	HISTAMINE	Eli Lilly	marketed	histamine	Histamine H3 receptor	1939-01-01
Betahistine Extended Release formulation	Betahistine Extended Release formulation	OBEcure Ltd.	marketed	Histamine H1 receptor agonist / H3 receptor antagonist	Histamine H1 receptor, Histamine H3 receptor
Merislon	Merislon	Zhan Yunfan	marketed		Histamine H3 receptor, Histamine H3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine H3 receptor inverse agonist class)

ACADIA Pharmaceuticals Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACP-104 — Competitive Intelligence Brief. https://druglandscape.com/ci/acp-104. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab